Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Fiche publication
Date publication
juin 2017
Journal
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BACHELLIER Philippe
Tous les auteurs :
Duconseil P, Périnel J, Autret A, Adham M, Sauvanet A, Chiche L, Mabrut JY, Tuech JJ, Mariette C, Régenet N, Fabre JM, Bachellier P, Delpéro JR, Paye F, Turrini O
Lien Pubmed
Résumé
To compare survival and impact of adjuvant chemotherapy in patients who underwent pancreaticoduodenectomy (PD) for invasive intraductal papillary mucinous neoplasm (IIPMN) and sporadic pancreatic ductal adenocarcinoma (PDAC).
Mots clés
Adjuvant chemotherapy, Invasive IPMN, Pancreatic adenocarcinoma, Staging
Référence
Eur J Surg Oncol. 2017 Jun;: